The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 170 participants.

Also called NCT04365517

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04365517
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04365517. Randomized; no masking; primary purpose treatment. Start 2021-12-29 (anticipated); primary completion 2022-03-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients
Acronym
SIDIACO
Condition
Covid19
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Sitagliptin
Lead sponsor
University of Milan (class: other)

Record details

Record id
cardio:ct-nct04365517
Content hash
665ead11adc3390424b1cbedabd475e0eea679bf663bf275cfac6f1f177092b1